Graft versus host reaction.pptx

4,095 views 10 slides Nov 09, 2022
Slide 1
Slide 1 of 10
Slide 1
1
Slide 2
2
Slide 3
3
Slide 4
4
Slide 5
5
Slide 6
6
Slide 7
7
Slide 8
8
Slide 9
9
Slide 10
10

About This Presentation

Graft versus host reaction


Slide Content

Graft versus host reaction

Transplant immunology Transplant immunology is the study of the immune response that occurs when an organ or tissue is moved (grafted) from one individual to another. A major problem following transplantation is that the immune system of the recipient sees the grafted tissue as 'foreign' and attacks and destroys it.

G raft V ersus H ost D isease D efinition A condition that occurs when donated stem cells or bone marrow (the graft) see the healthy tissues in the patient’s body (the host) as foreign and attack them. It can also occur after an organ transplant. Graft-versus-host disease can cause damage to the host’s tissues and organs, especially the skin, liver, intestines, eyes, mouth, hair, nails, joints, muscles, lungs, kidneys, and genitals. The signs and symptoms may be severe and life threatening. Graft-versus-host disease can occur within the first few months after transplant (acute) or much later (chronic). Also called GVHD.

Types There are two main categories of GVHD: A cute graft-versus-host disease C hronic graft-versus-host disease

A cute graft-versus-host disease This usually develops within the first 100 days after transplantation, but it can occur later. Acute GVHD can affect the skin, the gastrointestinal tract or the liver. Symptoms may include, A rash, with burning and redness of the skin. Nausea, vomiting, abdominal cramps, loss of appetite and diarrhea indicate involvement of the gastrointestinal tract. Jaundice (yellowing of the skin or eyes) may indicate that GVHD has injured the liver. Abnormalities of liver function would be noticed on blood test results.

Treatement Many patients who develop acute GVHD are successfully treated with increased immunosuppression in the form of corticosteroids (medicines such as prednisone, methylprednisolone, dexamethasone, beclomethasone and budesonide). The Food and Drug Administration (FDA) has approved the drug Ruxolitinib (Jakafi®) for the treatment of steroid-refractory acute GVHD in adult and pediatric patients 12 years and older.

C hronic graft-versus-host disease This is a syndrome that may involve a single organ or several organs. It is one of the leading causes of medical problems and death after an allogeneic stem cell transplantation. Symptoms may include . Mouth (A very dry mouth,Difficulty eating,Gum disease and tooth decay) Skin (A rash,Dry, tight, itchy skin,A change in skin color) Nails (Changes in nail texture,Hard, brittle nails,Nail loss) Scalp and Body Hair (Loss of hair on the head,Premature gray hair,Loss of body hair)

Cont... Gastrointestinal Tract (Loss of appetite,Unexplained weight loss ,Nausea,Vomiting,Diarrhea,Stomach pain) Lungs (Shortness of breath and difficulty breathing,Wheezing) Liver (Abdominal swelling,Jaundice) Muscles and Joints (Muscle weakness and cramps,Joint stiffness causing difficult full extension of fingers, wrists, elbows, knees, ankles.)

T reatment Prednisone is the standard first-line therapy for chronic GVHD Food and Drug Administration (FDA) has approved three drugs as second-line treatments: Ibrutinib (Imbruvica®) Belumosudil (Rezurock™) Ruxolitinib (Jakafi®)

THANK YOU
Tags